Previous close | 1.4350 |
Open | 1.4700 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 1.4700 - 1.4700 |
52-week range | 1.3488 - 3.8550 |
Volume | |
Avg. volume | 2,340 |
Market cap | N/A |
Beta (5Y monthly) | 1.59 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2040 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results from interim analyses The clinical study reports for FURI, CARES and NATURE in refractory invasive fungal infections are on target for delivery to GSK in the first half of 2024 which would trigger a $10 million develo
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M. ET. Guggenheim’s 6th Annual Biotechnology Conference Format: Fireside chat and one-on-one meetingsDate: Wed
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosisCombination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burden in lung and brain tissue compared to monotherapies JERSEY CITY, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and pr